clinical trial · NCT05182073
FT576 in Subjects With Multiple Myeloma
Multiple MyelomaMyelomaFT576 (Allogenic CAR NK cells with BCMA expression)CyclophosphamideFludarabineDaratumumabBendamustine
brief summary
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
started
Nov 10, 2021
primary completion
Sep 20, 2024
completion
Oct 18, 2024
last updated
Dec 12, 2025
official title
A Phase I Study of FT576 as Monotherapy and in Combination With Daratumumab in Subjects With Relapsed/Refractory Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol